On February 28th, Eli Lilly CEO Dai Wenrui stated in an interview that the company expects to launch the obesity drug Tirzepatide in India as early as next year.
During his keynote speech at the BioAsia conference held in the state of Trengana, India, Dai Wenrui pointed out that India should strengthen patent protection, abolish redundant policies, and establish a social safety net to win more investment from global pharmaceutical companies. (Reuters)